Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced it will present interim findings from three real-world studies in cutaneous ...

For patients with relapsed/refractory large B-cell lymphoma (LBCL), the autologous, CD19-directed, 4-1BB chimeric antigen ...

Chair of Tampa Light the Night, Laura Sherman, joins Gayle Guyardo, the host of the global health and wellness show, Bloom, ...

Patients with a rare blood cancer that has relapsed or become resistant to treatment have shown a high response rate to a ...

David Reitz has supported the Leukemia & Lymphoma Society with Light the Night walks raising over $46,000. This year he is ...

The FDA granted a priority review to acalabrutinib for the treatment of previously untreated adults with mantle cell lymphoma ...

Elicera Therapeutics describes how CAR T cells armed with neutrophil-activatingprotein can improve cancer therapy by inducing ...

An event aimed at spreading light and hope for patients and families dealing with the impacts of blood cancer returns Thursday.

AstraZeneca's Calquence receives FDA Priority Review for previously untreated mantle cell lymphoma, showing promising Phase 3 trial results in reducing disease progression by 27%. An FDA decision is ...

Most of the cancers were detected using standard age- and sex-based cancer screenings, suggesting the potential for ...

The City of Rockville will hold the Leukemia & Lymphoma Society’s Light The Night event on Saturday, Oct. 5. Light The Night ...

(Alliance News) - AstraZeneca PLC on Thursday said its cancer treatment Calquence obtained priority review by the US Food & Drug Administration for a form of lymphoma.